Molbio Diagnostics Ltd. Files DRHP for IPO: Aims to Raise Funds via Fresh Issue and OFS
Molbio Diagnostics Ltd., a point-of-care diagnostics company, has filed a draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO) comprising a fresh issue of up to ₹200 crore and an offer for sale (OFS) of 1.25 crore shares.
The promoters of the company, including Exxora Trading LLP and Dr. Chandrasekhar Bhaskaran Nair, will be offloading shares through the OFS. Additionally, investors such as V Sciences Investments Ltd., India Business Excellence Fund III, and Gopalkrishna Mangalore Kini will also be selling their stakes in the company.
Purpose of the IPO
The proceeds from the fresh issue will be utilized for various purposes, including funding capital expenditure towards the setting up of infrastructure for a research and development facility, Center of Excellence, and connected office space. Furthermore, the proceeds will also be used to purchase certain plant, machinery, and other equipment for the company’s Goa Unit I, Goa Unit II, and Visakhapatnam Unit. A portion of the proceeds will also be allocated for general corporate purposes.
It is worth noting that the company will not receive any proceeds from the OFS portion of the issue, as the sale of shares will be made by the existing shareholders.
Lead Book-Running Managers and Registrar
Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors will be the lead book-running managers of the issue. KFin Technologies Ltd. will act as the registrar for the IPO.
About Molbio Diagnostics Ltd.
Molbio Diagnostics is a point-of-care diagnostics company focused on expanding access to accurate, rapid, and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. The company has developed its ‘Truenat’ platform, which is a novel point-of-care (POC) polymerase chain reaction (PCR) platform that can operate in resource-limited settings since it is battery-operated, facilitating decentralized diagnosis within an hour.
As of March 31, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases. The company’s innovative technology has the potential to revolutionize the healthcare industry, particularly in resource-limited settings.
Indian Healthcare Industry Overview
The Indian healthcare industry has been growing rapidly, driven by an increasing demand for quality healthcare services. The industry is expected to continue growing, driven by factors such as an aging population, an increase in lifestyle-related diseases, and a growing awareness of the importance of healthcare.
The point-of-care diagnostics market in India is also expected to grow, driven by the increasing demand for rapid and accurate diagnostic tests. Molbio Diagnostics is well-positioned to capitalize on this trend, given its innovative Truenat platform and its focus on expanding access to healthcare technologies.
Investment Opportunities in the Indian Stock Market
The Indian stock market has been volatile in recent times, with the Nifty and Sensex experiencing significant fluctuations. However, the market is expected to continue growing, driven by factors such as a strong economic growth, a growing middle class, and a favorable business environment.
Investors looking to invest in the Indian stock market may consider investing in companies like Molbio Diagnostics, which have innovative technologies and a strong growth potential. However, it is essential to conduct thorough research and analysis before making any investment decisions.
For more information on the Indian stock market and investment opportunities, click here. To learn more about Molbio Diagnostics and its innovative Truenat platform, visit our website.